Modified FOLFIRINOX + Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing alternating chemotherapy treatments in patients with advanced pancreatic cancer who haven't been treated before. The goal is to see if this approach can keep the cancer from worsening for a longer time compared to using just one treatment. Gemcitabine has been a standard chemotherapy treatment for advanced pancreatic cancer since 1997.
Do I have to stop taking my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of modified FOLFIRINOX and Gemcitabine/Nab-Paclitaxel safe for humans?
Both modified FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel have been studied for safety in treating pancreatic cancer. Modified FOLFIRINOX may cause more nausea and blood-related side effects, while Gemcitabine plus Nab-Paclitaxel may lead to more nerve-related side effects. Overall, both treatments have different safety profiles, but they are generally considered safe for use in humans with pancreatic cancer.12345
What makes the drug combination of modified FOLFIRINOX and Gemcitabine/Nab-Paclitaxel unique for pancreatic cancer?
This drug combination is unique because it combines two powerful chemotherapy regimens, modified FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, which are both recommended as first-line therapies for advanced pancreatic cancer, offering potentially improved effectiveness and safety compared to using them separately.12367
What data supports the effectiveness of the drug combination Modified FOLFIRINOX + Gemcitabine/Nab-Paclitaxel for treating pancreatic cancer?
Research shows that both Modified FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel improve survival in patients with advanced pancreatic cancer compared to using Gemcitabine alone. These combinations are recommended as first-line therapies, indicating their effectiveness in treating this type of cancer.128910
Who Is on the Research Team?
Lyudmyla Berim, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Are You a Good Fit for This Trial?
This trial is for adults with metastatic pancreatic cancer who haven't had treatment for it yet. They need to be in good physical shape, have proper organ function, and agree to use birth control. People can't join if they've had certain other cancers, major surgery recently, infections like HIV or hepatitis, significant heart issues within the past 6 months, or are pregnant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive alternating cycles of mFOLFIRINOX and biweekly Gemcitabine plus Nab-Paclitaxel
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for long-term safety and survival outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Folfirinox
- Gemcitabine-nab-Paclitaxel
Folfirinox is already approved in United States, European Union for the following indications:
- Pancreatic cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lyudmyla Berim
Lead Sponsor